Zobrazeno 1 - 10 of 43 pro vyhledávání: '"Henrik Nordin"'
1
Response to 'To switch or not to switch':the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
Autor: Bente Glintborg, Anne Gitte Loft, Salome Kristensen, Inge Juul Sørensen, Frank Mehnert, Natalia Manilo, Johnny Lillelund Raun, Dorte Dalsgaard Pedersen, Jakob Espesen, Stavros Chrysidis, Hanne Merete Lindegaard, Lis Smedegaard Andersen, Oliver Hendricks, Merete Lund Hetland, Asta Linauskas, Niels Steen Krogh, Henrik Nordin, Inger Marie Jensen Hansen, D V Jensen, Susanne Højmark Jakobsen, Jolanta Grydehøj, Emina Omerovic, Kamilla Danebod, Emil Barner Dalgaard
Publikováno v: Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to To switch or not to switch' : The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4 . https://doi.org/10.1136/annrheumdis-2018-214952
Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b933c58f95be759c886ede1d15b976a
https://vbn.aau.dk/da/publications/9eba4499-3a28-4c04-b60d-d6ab174db85c
Zobrazit plný text záznamu
2
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Autor: Stavros Chrysidis, B. Glintborg, Niels Steen Krogh, Lis Smedegaard Andersen, Jimmi Sloth Olsen, Dorte Vendelbo Jensen, Jolanta Grydehøj, Michael Veedfald Sørensen, Salome Kristensen, Natalia Manilo, Merete Lund Hetland, Mette Klarlund, Oliver Hendricks, Inge Juul Sørensen, Sabine Sparre Dieperink, Asta Linauskas, Inger Marie Jensen Hansen, Henrik Nordin, Jakob Espesen, Kathrine Lederballe Grøn, Dorte Dalsgaard Pedersen, Lars Pedersen, Hanne Merete Lindegaard, Anne Gitte Loft
Publikováno v: Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L & Hetland, M L 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L, Hetland, M L & all departments of rheumatology in Denmark 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
ObjectivesAccording to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8575d080f35c2e1d089ff61ce2e62eb4
https://doi.org/10.1136/annrheumdis-2016-210742
Zobrazit plný text záznamu
3
To switch or not to switch:results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Autor: Johnny Lillelund Raun, Jolanta Grydehøj, D V Jensen, Inger Marie Jensen Hansen, Hanne Merete Lindegaard, Anne Gitte Loft, Emina Omerovic, Kamilla Danebod, Oliver Hendricks, Asta Linauskas, Henrik Nordin, Merete Lund Hetland, Stavros Chrysidis, Inge Juul Sørensen, Dorte Dalsgaard Pedersen, Susanne Højmark Jakobsen, Salome Kristensen, Frank Mehnert, Lis Smedegaard Andersen, Niels Steen Krogh, Emil Barner Dalgaard, B. Glintborg, Natalia Manilo, Jakob Espesen
Publikováno v: Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch : results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, no. 2, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474
ObjectivesReal-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c302890950b7f04e11e32e0f3a5fd9ec
https://vbn.aau.dk/da/publications/e6e32571-23f8-49ba-9a63-52682abf94c9
Zobrazit plný text záznamu
7
One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry
Autor: Bente Glintborg, Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Anne Gitte Loft, Oliver Hendricks, Chrysidis, S., Andersen, B. L., Johnny Lillelund Raun, Hanne Lindegaard, Jakob Espesen, Jakobsen, S. H., Inger Marie Jensen Hansen, Dalsgaard, E. B., Pedersen, D. D., Kristensen, S., Asta Linauskas, Andersen, L. S., Grydehøj, J., Krogh, N., Merete Lund Hetland
Publikováno v: Glintborg, B, Sørensen, I J, Omerovic, E, Mehnert, F, Manilo, N, Danebod, K, Jensen, D V, Nordin, H, Loft, A G, Hendricks, O, Chrysidis, S, Andersen, B L, Lillelund Raun, J, Lindegaard, H, Espesen, J, Jakobsen, S H, Jensen Hansen, I M, Dalsgaard, E B, Pedersen, D D, Kristensen, S, Linauskas, A, Andersen, L S, Grydehøj, J, Krogh, N & Hetland, M L 2018, ' One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 77, no. Suppl. 2, THU0189, pp. 313-314 . < https://ard.bmj.com/content/77/Suppl_2/313 >
University of Southern Denmark
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::271ebee78be7a4214928dcb613efc55b
https://portal.findresearcher.sdu.dk/da/publications/c84ac887-c412-46b6-88dd-2708ae8f8844
Zobrazit plný text záznamu
8
Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease:protocol for an open cohort study
Autor: Susanne Juhl Pedersen, Heidi Munk, Hanne Merete Lindegaard, Christoffer Tandrup Holst Nielsen, Henrik Nordin, Merete Lund Hetland, Estrid Høgdall, Søren Jacobsen, Torkell Ellingsen
Publikováno v: Kringelbach, T M, Glintborg, B, Hogdall, E V, Johansen, J S, Hetland, M L, Biomarker Protocol Study Group, Schlemmer, A, Kristensen, S & Meyer, M K 2018, ' Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease : protocol for an open cohort study ', BMJ Open, vol. 8, no. 2, e019325 . https://doi.org/10.1136/bmjopen-2017-019325
Kringelbach, T M, Glintborg, B, Hogdall, E V, Johansen, J S & Hetland, M L 2018, ' Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease : Protocol for an open cohort study ', BMJ Open, vol. 8, no. 2, e019325 . https://doi.org/10.1136/bmjopen-2017-019325
Biomarker Protocol Study Group, Ellingsen, T J & Lorenzen, T 2018, ' Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease : protocol for an open cohort study ' BMJ Open, vol. 8, no. 2, e019325 . https://doi.org/10.1136/bmjopen-2017-019325
BMJ Open
Lindegaard, H M, Bjørling-Poulsen, M, Ellingsen, T J, Munk, H L & Biomarker Protocol Study Group 2018, ' Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease : protocol for an open cohort study ', BMJ Open, vol. 8, no. 2, e019325, pp. e019325 . https://doi.org/10.1136/bmjopen-2017-019325
IntroductionThe introduction of biological disease-modifying antirheumatic drugs (bDMARDs) has improved the treatment of inflammatory rheumatic diseases dramatically. However, bDMARD treatment failure occurs in 30%–40% of patients due to lack of ef
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd31bdbf593160bdd4dde6875c2f8454
https://vbn.aau.dk/da/publications/15ff423a-7d11-463b-9bed-654d4d6893b0
Zobrazit plný text záznamu
10
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis:Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry
Autor: B. Glintborg, Abdiweli Awil Mohamoud, Mikkel Østergaard, D. G. A. Kraus, Laura Danielsen, Johnny Lillelund Raun, Niels Steen Krogh, Marcin Ryszard Kowalski, Inger Marie Jensen Hansen, Jens Kristian Pedersen, Lene Dreyer, Oliver Hendricks, Henrik Nordin, Anne Gitte Loft, R. Pelck, Jakob Esbesen, Nabil Al Chaer, Inge Juul Sørensen, Merete Lund Hetland, Annette Schlemmer, S. R. Christensen, Lone Salomonsen, Lis Smedegaard Andersen
Publikováno v: Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D, Christensen, S R, Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Hansen, I M J, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Jensen Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Objective.To compare baseline disease activity and treatment effectiveness in biologic-naive patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who initiate tumor necrosis factor inhibitor (TNFi) treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd77a674a776528ab55f6cdfa54f0c0
https://pure.au.dk/portal/da/publications/ankylosing-spondylitis-versus-nonradiographic-axial-spondyloarthritis(a4ec44b6-168b-422f-9d65-af16decdb758).html
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje